JDRF Center of Excellence
in Northern California

This Center is a cure accelerator and a high impact partnership combining the scientific expertise of Stanford University and the University of California, San Francisco (UCSF) within the collaborative structure and support that are hallmarks of JDRF. Investigators at the Center will seek to better understand and target the interactions between the immune system and the beta cell, in an effort to deliver first-generation, stem cell-based cures for type 1 diabetes (T1D).

These world-class researchers will:

  • Discover and explain how immune cells interact with islets and beta cells in T1D
  • Generate islets and immune cells from stem cells as the basis for next-generation cell therapies
  • Develop an islet transplant protocol that will induce tolerance and not require immunosuppression

Research Team

“One of the central challenges in type 1 diabetes has been identifying and targeting interactions required for autoimmune assault of human islets by immune cells. This team of superb and innovative investigators will combine novel hypotheses with modern tools to address such outstanding questions in type 1 diabetes pathogenesis. We envision that successful investigations in this crucial area of type 1 diabetes research by this Center of Excellence team will enable cell-based replacement therapies to move us closer to a cure for type 1 diabetes.”

Matthias Hebrok, Ph.D., University of California, San Francisco, and Seung Kim, M.D., Ph.D., Stanford University 

News & Blogs

  • JDRF, the leading global organization funding type 1 diabetes (T1D) research, today announced the launch of the JDRF Northern California Center of Excellence, to accelerate high-impact research at Stanford University and the University of California, San Francisco, to develop cures for T1D.

    September 04, 2019

  • Fall 2020 Progress Report

    Read the latest Report from these labs

  • Spring 2020 Progress Report

    Read the latest Report from these labs

Support our Work

Contact us to help us advance this critical work in curing T1D and improving lives.

Will Hall
Donor Relations Officer